Beam Therapeutics

Beam Therapeutics advances base-editing technologies for precise single-base changes in vivo. Its platform is therapeutic-delivery focused, not discovery-oriented like Algen’s AlgenCRISPR plus AlgenBrain combination. Pricing and business models center on clinical assets rather than platform partnerships for target deconvolution.